Rep. Lisa C. McClain Sells Encompass Health Corporation (NYSE:EHC) Stock

Representative Lisa C. McClain (R-Michigan) recently sold shares of Encompass Health Corporation (NYSE:EHC). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Encompass Health stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Encompass Health Stock Up 0.7%

EHC traded up $0.76 during trading on Wednesday, hitting $116.95. The company had a trading volume of 34,243 shares, compared to its average volume of 787,118. The company has a market cap of $11.77 billion, a PE ratio of 22.10, a P/E/G ratio of 2.20 and a beta of 0.91. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.06 and a quick ratio of 1.06. Encompass Health Corporation has a 1-year low of $87.85 and a 1-year high of $127.99. The business has a 50-day moving average of $120.96 and a 200-day moving average of $119.55.

Encompass Health (NYSE:EHC) last released its earnings results on Wednesday, March 16th. The company reported $0.93 earnings per share for the quarter. Encompass Health had a net margin of 9.33% and a return on equity of 18.19%. The company had revenue of $136.30 million during the quarter. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. As a group, analysts forecast that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Friday, January 2nd will be issued a $0.19 dividend. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $0.76 annualized dividend and a yield of 0.6%. Encompass Health’s dividend payout ratio is currently 14.37%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Citizens National Bank Trust Department acquired a new position in shares of Encompass Health during the third quarter worth approximately $26,000. WPG Advisers LLC acquired a new stake in Encompass Health in the 1st quarter valued at approximately $27,000. First Horizon Corp bought a new stake in Encompass Health during the 3rd quarter valued at $34,000. Westside Investment Management Inc. boosted its position in Encompass Health by 56.7% during the 3rd quarter. Westside Investment Management Inc. now owns 279 shares of the company’s stock worth $35,000 after acquiring an additional 101 shares during the period. Finally, Assetmark Inc. grew its stake in shares of Encompass Health by 88.1% in the third quarter. Assetmark Inc. now owns 299 shares of the company’s stock worth $38,000 after purchasing an additional 140 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on EHC shares. UBS Group lifted their target price on Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, October 2nd. Truist Financial raised their price objective on Encompass Health from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Raymond James Financial raised shares of Encompass Health to a “strong-buy” rating in a report on Friday, October 31st. KeyCorp raised their price target on shares of Encompass Health from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Finally, Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Sunday. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $142.86.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.